Cuur Diagnostics

Skin and Wound Panel

SKIN & WOUND PANEL

CUUR DiagnosticsTM is dedicated to maintaining the largest data set of infectious disease targets available in the world.
The US Centers for Disease Control and Preventions’ recent recommends, molecular diagnostic methods are essential for effective detection of Candida auris, a fungal pathogen that has garnered global attention due to its drug resistance and capability for highly invasive infections associated with high mortality rates in hospitals and long-term care facilities.

Acute and chronic wounds have become a significant healthcare problem in the US and as well as globally. Rapid and comprehensive identification of pathogens is critical to mitigate the risk of an acute infection becoming chronic, especially where patients with venous ulcers, diabetic ulcers or pressure ulcers who frequently suffer from prolonged failure to heal and may progress to the need for amputation. Correctly identifying the cause of a chronic wound as well as the local and systemic factors that may be contributing to poor wound healing is critical to successful wound treatment.

The CUUR Diagnostics’ SSI and SSTI wound pathogen detection panel is a comprehensive molecular panel covering 36 target species and tests for bacterial resistance simultaneously. This panel is tailored to every patient as the targets in this panel can be ordered as a whole or discretely. 

Compared to the industry-standard culture-based methodologies, the specificity and sensitivity of our SSI and SSTI wound panel allows for a more rapid and accurate diagnosis. On the forefront of quantitative molecular biology, CUUR Diagnostics has made advancements toward improving infectious disease diagnostics. Rapid diagnostic testing has the potential not only for enhancing patient care and helping to preserve the effectiveness of current antibiotic agents, but also boosting capabilities for antimicrobial resistance surveillance and new
antibiotic development. 

The CUUR Diagnostics initiative is focused on improving patient, provider and facility healthcare outcomes for infectious disease by offering tremendous flexibility, extremely precise diagnostics, and improved antibiotic stewardship.  

The Science

Historically standard microbiology cultures have been used to identify bacterial presence within SSIs and SSTIs. However, the culture-based method has been proven inadequate due to limited cultivation, poor quantification, and diagnostic selection bias of bacterial growth within laboratory settings. Additionally, the main disadvantage of culture based antibiotic resistance which also is considered as phenotyping, is the time to perform the testing.

Making Provider and Patient Lives Better

Molecular techniques have surpassed culture-based techniques in that molecular qPCR testing has:

• Enhanced sensitivity – Quantitative PCR is able to detect a lower number of bacteria than culture methods are capable of

• Enhanced specificity – Cultures are often misidentified by the phenotypic appearance whereas molecular analysis verifies bacterial presence by targeting bacterial DNA

• The ability to detect non-viable bacteria – It is impossible to culture bacteria that is no longer alive as it will no longer grow. 

• A shorter turnaround time

CUUR Diagnostics provides the most comprehensive examination of the bacterial and fungal organisms available on the market empowering providers in wound diagnostics, limb preservation, avoidance of adverse events and prevention of unnecessary antibiotic prescribing.

Helix DNA
TARGETS

Gram Negative Bacteria 
BacteriaKlebsiella pneumoniae
BacteriaKlebsiella oxytoca
BacteriaEscherichia coli
BacteriaEnterobacter aerogenes
BacteriaAcinetobacter baumannii
BacteriaPseudomonas aeruginosa
BacteriaProteus mirabilis
BacteriaBartonella henselae
BacteriaStenotrophomonas maltophilia
BacteriaBacteroides fragilis

Gram Positive Bacteria 
BacteriaStaphylococcus aureus
BacteriaStreptococcus agalactiae
BacteriaStreptococcus pyogenes
BacteriaStaphylococcus epidermidis
BacteriaEnterococcus faecalis
BacteriaStreptococcus dysgalactiae
BacteriaCorynebacterium riegelii
BacteriaFinegoldia magna (Peptostreptococcus magnus)
BacteriaClostridium perfringens
BacteriaPeptostreptococcus anaerobius
BacteriaPropionibacterium acnes

Fungal 
FungalStaphylococcus aureus
FungalStreptococcus agalactiae
FungalStreptococcus pyogenes

AbR 
AbRESBL, blaOXA
AbRMethicillin, mecA
AbRESBL, blaKPC
AbRVancomycin, vanA
AbRVancomycin, vanB
AbRAminoglycoside, aac(6’)-lb-cr
AbRMacrolide, ermB
AbRAmpicillin, ampC
AbRTetracycline, tetS
AbRQuinolone, qnrA
AbRQuinolone, qnrS
AbRCarbapenem Resistance, oxa-48

Infectious Disease Care

D I A G N O S T I C S

STATISTICALLY SPEAKING
  • In the US, 8.2 million patients receiving Medicare benefits suffer from chronic wounds
  • Medicare spends over $32 billion annually on wound treatment.